174 related articles for article (PubMed ID: 38169059)
1. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
[TBL] [Abstract][Full Text] [Related]
2. Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors.
Shao C; Ren Y; Zhou H; Chen C; Dettman EJ; Lee LC; Cristescu R; Gozman A; Jin F; Zhou W
JCO Precis Oncol; 2023 Sep; 7():e2300195. PubMed ID: 37972338
[TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
4. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
Shao C; Chang MS; Lam FC; Marley AR; Tang H; Song Y; Miller C; Brown M; Wan I; Han J; Adeboyeje G
J Oncol; 2022; 2022():5830475. PubMed ID: 35909902
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract][Full Text] [Related]
7. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S; Oza A; Hall G; Pardo B; Madry R; Cibula D; Klat J; Montes A; Glasspool R; Colombo N; Pete I; Herrero Ibáñez A; Marín MR; Ilieva R; Timcheva C; Di Maio M; Blakeley C; Taylor R; Barnicle A; Clamp A
Gynecol Oncol; 2023 May; 172():121-129. PubMed ID: 37030280
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
10. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
11. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
Pfarr N; Merkelbach-Bruse S
Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
[TBL] [Abstract][Full Text] [Related]
12. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
14. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
15. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
17. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases.
Shui IM; Burcu M; Shao C; Chen C; Liao CY; Jiang S; Cristescu R; Parikh RB
Prostate Cancer Prostatic Dis; 2023 Dec; ():. PubMed ID: 38057611
[TBL] [Abstract][Full Text] [Related]
18. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitor Insensitivity to
Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
[TBL] [Abstract][Full Text] [Related]
20. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]